American Diabetes Association
Browse

The role of adaptive and innovative trial designs in diabetes research: A scoping review

Download (412.03 kB)
figure
posted on 2025-11-20, 18:15 authored by Ashni Goshrani, Rose Lin, Michele Gaca, Christine Somerville, Kamlesh Khunti, Elizabeth Holmes-Truscott, Negar Naderpoor, David O’Neal, Leonid Churilov, Rury Holman, Elif Ekinci
<p dir="ltr">Background: Adaptive and master protocol clinical trials offer significant advantages for diabetes research, including enhanced efficiency and personalized treatment strategies. </p><p dir="ltr">Purpose: This scoping review aimed to systematically map the use of adaptive and master protocol designs in interventional trials for type 1 and type 2 diabetes, identify research gaps and highlight opportunities for broader implementation.</p><p dir="ltr">Data Sources: A systematic literature search was performed using MEDLINE, Embase, CENTRAL, Emcare, Global Health, Web of Science, and clinical trial registries. Grey literature searches complemented database findings. </p><p dir="ltr">Study Selection: Studies using adaptive, platform, basket, or umbrella trial designs in people with type 1 or type 2 diabetes were included.</p><p dir="ltr">Data Extraction: Data were charted using a standardized form. Extracted variables included diabetes type, trial design, adaptive features, interventions, endpoints, and key findings.</p><p dir="ltr">Data Synthesis: Of 396 articles screened, six published adaptive trials met inclusion criteria: three in type 1 diabetes, one in type 2 diabetes, and two in diabetes-related neuropathy. Most used adaptive features for dose-finding, response-adaptive randomisation and sample size re-estimation. No published platform, basket, or umbrella trials were identified. Six ongoing adaptive trials in type 1 diabetes were identified through registry searches, four under an adaptive platform master protocol.</p><p dir="ltr">Limitations: Despite a comprehensive search, some grey literature and unpublished studies may have been missed. Risk of bias was not assessed, consistent with scoping review methodology. </p><p dir="ltr">Conclusions: Adaptive and master protocol trials remain rare in diabetes. Overcoming barriers through targeted training and awareness, robust regulatory frameworks, and strategic incentives could support broader adoption. </p>

Funding

E.H.-T. is supported by core funding to The Australian Centre for Behavioural Research in Diabetes derived from the collaboration between Diabetes Victoria and Deakin University. In the past three years, E.H.-T. has received unrestricted educational grants and / or research funding paid to her institution (ACBRD) from Breakthrough T1D, Diabetes Australia, Diabetes Australia Research Program, Diabetes Canada, Diabetes Victoria, The DiaTribe Foundation. E.I.E. is supported by grants from MRFF, NHMRC, MTP Connect, Sir Edward Weary Dunlop Research Foundation.

History

Usage metrics

    Diabetes Care

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC